One of Australia’s most influential philanthropic institutions, the Sylvia and Charles Viertel Charitable Foundation, is celebrating 30 years of supporting local health and medical research with more than $90 million invested and a legacy of breakthroughs now shaping clinical care around the world.

Australia has taken a significant step toward building sovereign advanced biomanufacturing capability with the official opening of the Viral Vector Manufacturing Facility in Sydney.

“MSAC’s position is a powerful endorsement of RECELL’s clinical impact and the difference it makes in patients’ lives,” said Katie Bush, Senior Vice President, Scientific and Medical Affairs at AVITA Medical.

Two leading Australian researchers have been awarded prestigious CSL Centenary Fellowships, each valued at $1.25 million over five years, to advance groundbreaking research in lifelong immunity and AI-driven protein design.

Anteris Technologies (ASX:AVR) has announced one-year clinical results demonstrating sustained favourable hemodynamics and excellent safety outcomes for its DurAVR Transcatheter Heart Valve in patients with small aortic annuli, including no valve-related mortality and a very low rate of prosthesis-patient mismatch.

A pioneering RNA therapy being developed in Melbourne could transform the treatment of lupus, offering new hope to thousands of Australians living with the chronic autoimmune disease.

“After positive feedback from FDA during our recent Type D meeting, we are excited to initiate start-up activities for the phase 1 clinical trial and are delighted to have found an excellent partner in SAPRO,” said Michael Baker, Chief Executive Officer and Managing Director of Arovella.

AusBiotech has announced that Queensland will host its international conference for 2026 and 2027, and Dr Marthe D’Ombrain has been re-elected to its board.

Myrio Therapeutics has entered a research collaboration with the Perelman School of Medicine at the University of Pennsylvania and NYU Langone Health to accelerate the development of next-generation T cell immunotherapies for solid tumours.

MTPConnect has signed a Memorandum of Understanding with the Ministry of Health of the Kingdom of Saudi Arabia to strengthen bilateral cooperation and support the growth of life sciences companies in both countries.

Immuron (ASX:IMC) has officially launched PROIBS in Australia, entering the country’s sizeable over-the-counter digestive health market with a new therapeutic option for patients living with Irritable Bowel Syndrome.

PolyNovo (ASX:PNV) has announced that David Williams has resigned as Chair of the company's Board, bringing to a close an 11-year tenure that has coincided with the company’s transformation from an early-stage medical technology venture to a global wound care business.

PYC Therapeutics (ASX:PYC) has reported continued clinical and operational progress across its pipeline of RNA-based precision medicines, alongside a strong financial position, in its third-quarter 2025 shareholder update.

Cann Group (ASX:CAN) has unveiled a major financial reset, announcing an 81 per cent reduction in debt and a $9 million capital raising, providing what CEO Jenni Pilcher describes as “a clean foundation” for the company’s next phase of growth.

Snoretox has been recognised on the global stage, taking home the 2025 Innovation Award at the KC Animal Health Summit in Kansas City.

With more than 2,900 life sciences organisations employing one in every 60 Australians, the sector continues to grow as a pillar of the nation’s future innovation economy. This week’s announcements, from expanding trade facilitation to forging international partnerships and welcoming record global delegates, underscore Australia’s ambition to play a leading role in the global life sciences landscape.

Starpharma Holdings (ASX:SPL) has received an upfront payment of US$5.5 million (A$8.5 million) from Genentech, a member of the Roche Group, marking the formal commencement of their recently announced license agreement focused on developing dendrimer-drug conjugates for selected oncology targets.

PYC Therapeutics (ASX:PYC) has taken a significant step forward in its goal to deliver the first treatment for Autosomal Dominant Optic Atrophy, announcing the initiation of a global repeat-dose Phase 1b clinical study of its investigational RNA therapy, PYC-001.

Telix Pharmaceuticals (ASX:TLX) has dosed the first patient in its Phase 1 clinical trial evaluating TLX090 (¹⁵³Samarium (Sm)-DOTMP), a next-generation therapeutic radiopharmaceutical being developed to treat pain associated with metastatic bone disease.